Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.
Industry Group: Pharmaceuticals
Country/Region: China
Identifier: SHG:603707
Nanjing King-Friend Biochemical Pharmaceutical Co Ltd is a China-based company engaged in the research and development, import and export of medicines and health products. The main products of the company are Heparin sodium and low molecular weight heparin. Geographically, the business activities are carried out through China and it exports the product mainly to the European and American countries.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 841 out of 851
Universe
Global Universe 14236 out of 15104
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the non-India based rated subjects, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Laboratorios Farmaceúticos Rovi SA |
16.1
Low
|
31 out of 851 |
J.B. Chemicals & Pharmaceuticals Ltd. |
27.2
Medium
|
297 out of 851 |
Gland Pharma Ltd. |
27.2
Medium
|
301 out of 851 |
Betta Pharmaceuticals Co., Ltd. |
36.1
High
|
705 out of 851 |
Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. |
42.5
Severe
|
841 out of 851 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.'s Management of ESG Material Risk is Weak
How do the ESG Risk Ratings work?
Top Material ESG Issues for Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.
Understand how exposed companies are to specific material ESG issues and how well companies are managing these issues.
What are Material ESG Issues?
Material ESG issues are issues that are considered to be financially material to a given company in a relevant sub-industry.
Controversy Rating
Highest Controversy level that has impacted Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.'s ESG Risk Rating in the last three years
Highest Controversy Level